Baseline demographics and clinical characteristics
| ATTAIN | AIM | |||
|---|---|---|---|---|
| Abatacept (n=258) | Placebo (n=133) | Abatacept (n=433) | Placebo (n=219) | |
| Age, years | 53.4±12.4 | 52.7±11.3 | 51.5±12.9 | 50.4±12.4 |
| Female, % | 77 | 80 | 78 | 82 |
| Caucasian, % | 96 | 93 | 88 | 88 |
| Duration of RA, years | 12.2±8.5 | 11.4±8.9 | 8.5±7.3 | 8.9±7.1 |
| HAQ-DI (scale of 0–3) | 1.8±0.6 | 1.8±0.6 | 1.7±0.7 | 1.7±0.6 |
| DAS28 (CRP), mean score | 6.5±0.9 | 6.5±0.8 | 6.4±0.08 | 6.4±0.11 |
| Patient global assessment (0–100) | 69±20 | 69±20 | 63±21 | 63±22 |
| Pain (0–100) | 71±20 | 69±19 | 63±21 | 63±21 |
| Fatigue (0–100) | 73±19 | 71±20 | 63±23 | 66±23 |
| Sleep disturbance (0–100) | 50.0±26.5 | 47.4±24.1 | 46.4±27.2 | 45.7±25.4 |
| Snoring | 36.6±30.5 | 39.2±35.6 | 35.4±32.9 | 38.2±32.4 |
| Awake short of breath or with headache | 18.5±24.0 | 15.3±21.3 | 19.0±24.4 | 21.1±25.2 |
| Sleep adequacy | 37.2±25.6 | 38.9±23.8 | 47.4±29.5 | 42.9±28.0 |
| Sleep somnolence | 46.0±22.9 | 41.2±22.5 | 39.8±22.7 | 42.1±21.0 |
| Sleep Problems Index I | 47.1±19.1 | 43.4±22.5 | 41.1±21.2 | 42.9±19.1 |
| Sleep Problems Index II | 48.9±19.0 | 45.9±18.4 | 43.0±20.8 | 44.3±19.1 |
Data are mean±SD unless otherwise stated.
AIM, Abatacept in Inadequate responders to Methotrexate; ATTAIN, Abatacept Trial in Treatment of Antitumor necrosis factor; CRP, C-reactive protein; DAS28, Disease Activity Score 28; HAQ-DI, Health Assessment Questionnaire Disability Index; RA, rheumatoid arthritis.